13 results about "Coiled coil" patented technology

Myocilin-binding agents including antibodies and antigen binding fragments thereof and fusion proteins that immunospecifically bind the coiled-coil domain of myocilin but do not bind to misfolded myocilin are provided herein. The disclosed antibodies and antigen binding fragments and fusion proteins are useful for the detection and extraction of natively folded myocilin from a sample.

The present invention relates generally to a plant cell-surface immune receptor engineered to modulate an immune response in a plant, cell or seed, as well as nucleic acid molecules encoding the engineered receptor, and methods of use. In particular, the present invention relates to a plant cell-surface immune receptor into which a coiled-coil (CC) motif is integrated to enhance or modify the plant's immune response, with utility in reducing pathogen infection and improving pathogen resistance.

The present invention relates to a hepatitis delta virus (HDV) polypeptide comprising an antigenic domain comprising an amino acid sequence of SEQ ID NO:1 or an amino acid sequence at least 60% identical thereto, wherein said polypeptide (i) is devoid of a coiled-coil domain consisting of the amino acid sequence of SEQ ID NO:2 or an amino acid sequence at least 60% identical thereto; or (ii) further comprises said coiled-coil domain, wherein said coiled-coil domain comprises at least one of the following mutations: (I) the amino acid at position 20 is not tryptophan, and (II) the amino acid at position 50 is not tryptophan. Moreover, the present invention relates to proteins, kits, polynucleotides, host cells, methods, and devices related thereto.

The disclosure is in the field of immunology and oncology, especially for treating, preventing, or inhibiting proliferative diseases, particularly cancer, infectious diseases and disorders associated with dysfunction of TNF cytokines. The disclosure relates to a novel SPD-TNFSF fusion protein including a TNF-superfamily (TNFSF) ligand, or receptor binding domain thereof, fused to a coiled-coil domain of surfactant protein-D (SPD). Also provided a trimeric or multimeric fusion protein including a plurality of SPD-TNFSF fusion proteins. The disclosure also provides an expression vector as mRNA, plasmid or virus including an isolated nucleotide sequence encoding the SPD-TNFSF fusion protein and a cell or a pharmaceutical composition including thereof.

The present application relates to the field of medical diagnosis, and provides a combined marker for predicting the curative effect of target immune drug for primary liver cancer and application thereof, wherein the combined marker is folate receptor gamma gene FOLR3, stratified protein gene SFN and coiled-coil domain containing 9 gene CCDC9 derived from peripheral blood leukocyte mRNA.The present application performs combined detection based on multiple peripheral blood leukocyte markers, and compared with a single molecular marker, can reduce errors caused by individual expression difference of a single index to some extent, so that the detection result is more accurate.The curative effect prediction model constructed based on detection of peripheral blood leukocyte mRNA level change can specifically recognize and detect in the early stage of tumor formation, has high sensitivity and high specificity, provides an important means for reasonable use of target immune drug for liver cancer patients sensitive or resistant to target immune drug, and has great significance for effective treatment of liver cancer in China.

The invention discloses a self-assembled nanofiber antibacterial peptide based on a coiled spiral structure and a preparation method and application thereof, and belongs to the technical field of biology, and the amino acid sequence is as shown in SEQ ID No.1. The preparation method comprises the following steps: adopting an alpha-spiral heptapeptide repetitive sequence (abcdefg) 4 template, and selecting lysine to provide positive charges at positions b and c; leucine and isoleucine are respectively filled to a position a and a position d to provide intermolecular hydrophobic force, and lysine and glutamic acid are selected to be respectively filled to a position e and a position g to provide intermolecular electrostatic force; the position f of the center of the hydrophilic surface of the polypeptide is filled with tryptophan to optimize the hydrophobicity of the polypeptide, and the sequence is repeated for four times on the basis. The invention further discloses application of the antibacterial peptide in preparation of drugs for treating gram-positive bacteria or / and gram-negative bacteria infectious diseases. The antibacterial peptide disclosed by the invention has relatively strong antibacterial activity and good biocompatibility, and provides an effective technical support for developing a novel antibacterial drug.

Compositions of anti-inflammatory peptides and methods of use thereof are provided. The peptides include N-terminal, palmitoylated peptides covering / derived from a coiled-coil region of CRACR2A. Methods include reducing inflammation and / or inhibiting a STIM1-CRACR2A interaction in a subject in need thereof by administering a composition of the present disclosure. Exemplary compositions include palmitoylated peptides having between about 10 and 20 amino acids.

The invention belongs to the technical field of biological vaccines. The invention particularly relates to a recombinant bacteriophage capable of inducing mucosal immune response and application of the recombinant bacteriophage. Specifically, a pVIII capsid protein is utilized to display a SpyCatcher protein on the surface of an M13 bacteriophage particle (for example, through a pVIII-trimer parallel coiled spiral structure coiled-coil-SpyCatcher structure), and an antigen protein is coupled through SpyCatcher and SpyTag, so that the antigen protein is efficiently displayed on the surface of the bacteriophage, and the recombinant M13 bacteriophage is obtained. The capsid protein of the recombinant M13 bacteriophage can display hundreds of copies of same epitopes, the natural structure on the surface of a pathogen is simulated by the highly dense and highly repeated antigen arrangement mode, a B cell receptor is effectively cross-linked, a strong humoral immune response is induced, and no extra adjuvant is needed.

The present invention is directed to a method for treating primary ciliary dyskinesia (PCD) using a splicing modulator, such as an antisense oligonucleotide, capable of inducing the skipping of exon 3 of the coiled-coil domain containing 40 (CCDC40) pre-mRNA. Also provided is a composition comprising the splicing modulator, and use of same.

In alternative embodiments, provided are peptides and peptide-comprising compositions, including products of manufacture and kits, and methods, for modulating myosin subfragment-2 coiled coil stability. In alternative embodiments, a peptide modulator of myosin subfragment-2 coiled coil stability as provided herein is administered to an individual in need thereof for: increasing exercise tolerance in a subject with heart failure; reducing hospitalization in a subject with heart failure; improving quality of life in a subject with heart failure; decreasing morbidity in a subject with heart failure; decreasing mortality in a subject with heart failure; modulating skeletal muscle activity for purposes of impacting patient weight; and / or, modulating skeletal muscle activity for purposes of ameliorating consequences of skeletal muscle diseases such as sarcopenia, muscular dystrophies, muscle cramps, and nemaline myopathies.

The present invention relates to a type I or II transmembrane fusion protein comprising, successively:a) optionally, a signal peptide;b) a protein or a peptide of interest;c) a coiled-coil domain; andd) a domain for anchoring in the plasma membrane, consisting of a transmembrane segment and a cytosolic segment.It also relates to the virus-like particles obtained with this fusion protein.

The invention relates to the technical field of biology, in particular to extracellular matrix polymer protein and a preparation method and application thereof. The invention also relates to a recombinant protein composition, a polynucleotide composition, a carrier composition, a recombinant cell composition and an active additive or preparation used in the fields of tissue engineering, pharmacy or beauty and skin care related to the extracellular matrix multimeric protein. The extracellular matrix polymer protein comprises a first subunit and a second subunit, the first subunit comprises a first coiled-coil domain and at least one extracellular matrix protein fragment; the second subunit comprises a second coiled-coil domain and at least one extracellular matrix protein fragment; the first subunit and the second subunit are non-covalently bound via the first coiled helical domain and the second coiled helical domain. The extracellular matrix polymer protein overcomes at least one of the defects of rigid multi-module assembly structure, insufficient activity retention and low yield after fusion of the traditional artificially prepared extracellular matrix protein.

The present invention relates to a lipopeptide building block consisting of(i) a peptide moiety comprising a coiled coil peptide chain segment, wherein said coiled coil peptide chain segment comprises 3 to 8 repeat units, and wherein said repeat unit consists of the sequence IEKKIE-X0 (SEQ ID NO:58), wherein X0 represents an amino acid, and wherein preferably said repeat unit consists of the sequence selected from IEKKIEG (SEQ ID NO:59), IEKKIEA (SEQ ID NO:12) or IEKKIES (SEQ ID NO:13), and wherein further preferably said repeat unit consists of the sequence IEKKIES (SEQ ID NO:13);(ii) a lipid moiety comprising, preferably consisting of, the formula LM-Iwherein R1 and R2 are independently C11-15alkyl, wherein preferably R1 and R2 are independently —C11H23, —C13H27 or —C15H31, and wherein further preferably R1 and R2 are —C15H31; and wherein R3 is hydrogen or —C(O)C11-15alkyl, and wherein preferably R3 is H or —C(O)C15H31;and wherein said lipid moiety is linked to said peptide moiety, wherein the wavy line in formula LM-I indicates the linkage site to said peptide moiety, and wherein preferably said lipid moiety is linked to the N-terminus of said peptide moiety, as well as conjugates comprising said lipopeptide building blocks to which antigens are coupled, bundles of such conjugates, synthetic virus-like particles (SVLPs) comprising at least one bundle of conjugates and pharmaceutical compositions comprising the same. The present invention further relates to said conjugates, bundles of conjugates, said SVLPs and said pharmaceutical compositions for use as a medicament, as vaccines and for use in methods of preventing or treating a disease, preferably selected from infectious diseases, allergies and cancer, and generally to efficiently induce antigen specific immune responses.